Investigational live attenuated varicella vaccine

BIOLOGICAL5 trials

Sponsors

Sinovac (Dalian) Vaccine Technology Co., Ltd., China National Biotec Group Company Limited

Conditions

Varicella

Phase 1

A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children

CompletedNCT02965404

Sinovac (Dalian) Vaccine Technology Co., Ltd.Varicella

Start: 2016-04-30End: 2016-08-31Target: 270Updated: 2017-10-26

Phase 3

A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines

CompletedNCT02981836

Sinovac (Dalian) Vaccine Technology Co., Ltd.Varicella

Start: 2016-08-31End: 2017-09-30Updated: 2017-10-26

An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization

CompletedNCT05150392

Sinovac (Dalian) Vaccine Technology Co., Ltd.Varicella

Start: 2018-07-11End: 2020-08-14Updated: 2021-12-09

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

Active, not recruitingNCT05669625

China National Biotec Group Company LimitedVaricella

Start: 2022-12-26End: 2026-09-14Updated: 2023-06-18

Phase 4

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

Enrolling by invitationNCT05095701

Sinovac (Dalian) Vaccine Technology Co., Ltd.Varicella

Start: 2021-12-18End: 2025-10-01Target: 703Updated: 2025-01-27

Related Papers

Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years

Vaccines2022-04-223 citations

Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial.

2019-01-0422 citations